Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 655 of 5804
-
New stem cell infusion could boost transplant success in rare blood disorder
Disease control ENROLLING_BY_INVITATIONEfficacy and Safety of Sequential Infusion of Hypoxic 3D-Cultured Umbilical Cord Mesenchymal Stem Cells in Haploidentical Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia: A Multicenter, Randomized, Phase 1 Trial
Phase: PHASE1, PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Shorter PTSD therapy shows promise for veterans who drop out early
Symptom relief CompletedCognitive Processing Therapy (CPT) consists of discrete therapeutic components that are delivered across 12 sessions, but most Veterans never reach session 12, and those who drop out receive only 4 sessions on average. Veterans drop out because of time constraints, logistics, and…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New hope for chinese men with tough prostate cancer: targeted drug takes on standard care
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Timing of radiation may cut brain cancer spread
Disease control Recruiting nowThe research question is whether a single fraction of preoperative radiosurgery can reduce the incidence of leptomeningeal disease 12 months following resection of a brain metastasis (BM) as compared with 5 fractions of postoperative stereotactic radiotherapy.
Phase: NA • Sponsor: Susanne Rogers • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New balloon treatment may be safer for heart patients prone to bleeding
Disease control OngoingDCB-HBR trial is prospective, multi-center, open-label, randomized controlled, noninferiority trial. The aim of the study is to compare clinical outcomes of drug-coated balloon (DCB) with drug-eluting stent (DES) for treatment of de-novo coronary lesion in patients with high ble…
Phase: NA • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug aims to slow lung scarring in IPF
Disease control OngoingThis is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Phase: PHASE2 • Sponsor: Daewoong Pharmaceutical Co. LTD. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a Triple-Drug cocktail outsmart Treatment-Resistant colorectal cancer?
Disease control TerminatedThis Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug shows promise in Late-Stage Sjogren's trial
Disease control CompletedA randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Brain chip offers hope for untreatable depression
Disease control Recruiting nowChronic intracalvarial cortical stimulation is a minimally invasive method involving the neurosurgical placement of an electrode above the inner table of the skull. Over time, intracalvarial cortical stimulation is intermittently activated to modulate locally and distally connect…
Phase: NA • Sponsor: Inner Cosmos Inc • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Hope for rare immune disease: new drug enters final testing
Disease control Recruiting nowThe primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Phase: PHASE3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a cannabidiol drug help heal inflamed hearts?
Disease control CompletedMulti-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within 10 days of the diagnostic CMR to CardiolRx or placebo. CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahyd…
Phase: PHASE2 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a breastfeeding drug mend broken hearts after childbirth?
Disease control Recruiting nowThe study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breas…
Phase: PHASE4 • Sponsor: Dennis M. McNamara, MD, MS • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Engineered immune cells take on childhood brain cancer in first human trial
Disease control OngoingThis is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependym…
Phase: PHASE1 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill shows promise for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
Phase: PHASE1, PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or that has spread from where it first started (prima…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New tailored therapy offers hope for older hodgkin lymphoma patients
Disease control OngoingThis is a multi-center, open-label phase II study to assess the efficacy of a novel fitness-adapted regimen in previously untreated older patients with classical Hodgkin lymphoma. All participants will receive up to a total of 8 cycles of pembrolizumab (Q6 week dosing). The first…
Phase: PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New immunotherapy cocktail shows promise for tough lung cancer
Disease control CompletedThis is an open-label, multi-center, Phase 2 study in subjects with treatment-naïve locally advanced (unresectable and unable to receive radical chemoradiotherapy) or metastatic PD-L1-positive non-small cell lung cancer (NSCLC) who have received systemic therapy.
Phase: PHASE2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Precision freezing targets prostate cancer, spares healthy tissue
Disease control Recruiting nowTo learn if using cryotherapy to treat only the part of the prostate known to contain cancer is effective in controlling prostate cancer
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Hospital trial aims to stop deadly c. diff before it starts
Prevention Recruiting nowClostridioides difficile (C. difficile) is the most common healthcare-associated pathogen, causing \>500,000 infections and \>29,000 deaths per year in the US. Traditional approaches to reduce hospital-onset CDI focus on identifying, isolating, and treating symptomatic patients t…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 09:10 UTC
-
Ovarian cancer hope: new combo shows promise in shrinking tumors before surgery
Disease control CompletedThe primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor deoxyribonucleic acid (ctDNA) at Cycle 3 (ΔctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combinatio…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC